82 FR 48104 - National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 198 (October 16, 2017)

Page Range		48104-48104
FR Document		2017-22259

Federal Register, Volume 82 Issue 198 (Monday, October 16, 2017)

[Federal Register Volume 82, Number 198 (Monday, October 16, 2017)]
[Notices]
[Page 48104]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-22259]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; NIAID Clinical Trial Planning Grant 
(R34) and Implementation Cooperative Agreement (U01).
    Date: November 6-9, 2017.
    Time: 9:00 a.m. to 5:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 5601 Fishers Lane, 
Rockville, MD 20892, (Telephone Conference Call).
    Contact Person: Geetanjali Bansal, Ph.D., Scientific Review 
Officer, Scientific Review Program, Division of Extramural 
Activities, Room 3G49, National Institutes of Health/NIAID, 5601 
Fishers Lane, MSC 9834, Bethesda, MD 20892-9834, (240) 669-5073, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: October 10, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-22259 Filed 10-13-17; 8:45 am]
 BILLING CODE 4140-01-P

48104 Federal Register / Vol. 82, No. 198 / Monday, October 16, 2017 / Notices

to provide additional information to on the Committee’s Web site: http:// would constitute a clearly unwarranted
HRSA by October 24, 2017, 12:00 p.m. www.hrsa.gov/advisorycommittees/ invasion of personal privacy.
Eastern Time. Please see contact mchbadvisory/heritabledisorders. Name of Committee: National Institute of
information below. Members of the public will have the Allergy and Infectious Diseases Special
FOR FURTHER INFORMATION CONTACT: opportunity to provide comments. All Emphasis Panel; NIAID Clinical Trial
Anyone requesting information comments are part of the official Planning Grant (R34) and Implementation
regarding the ACHDNC should contact Committee record. To submit written Cooperative Agreement (U01).
Ann Ferrero, Maternal and Child Health comments or request time for an oral Date: November 6–9, 2017.
Time: 9:00 a.m. to 5:30 p.m.
Bureau (MCHB), HRSA, in one of three comment at the meeting, please register
Agenda: To review and evaluate grant
ways: (1) Send a request to the following online by 11:59 p.m. Eastern Time on applications.
address: Ann Ferrero, MCHB, HRSA November 2, 2017, at http:// Place: National Institutes of Health, 5601
5600 Fishers Lane, Room 18N100C, www.achdncmeetings.org/. To ensure Fishers Lane, Rockville, MD 20892,
Rockville, MD 20857; (2) call 301–443– all individuals who have registered and (Telephone Conference Call).
3999; or (3) send an email to: AFerrero@ requested time for oral comments are Contact Person: Geetanjali Bansal, Ph.D.,
hrsa.gov. accommodated, the allocated time for Scientific Review Officer, Scientific Review
SUPPLEMENTARY INFORMATION: The comments may be limited. Individuals Program, Division of Extramural Activities,
associated with groups or who plan to Room 3G49, National Institutes of Health/
ACHDNC provides advice to the NIAID, 5601 Fishers Lane, MSC 9834,
Secretary of HHS on the development of provide comments on similar topics
Bethesda, MD 20892–9834, (240) 669–5073,
newborn screening activities, may be asked to combine their geetanjali.bansal@nih.gov.
technologies, policies, guidelines, and comments and present them through a
(Catalogue of Federal Domestic Assistance
programs for effectively reducing single representative. No audiovisual Program Nos. 93.855, Allergy, Immunology,
morbidity and mortality in newborns presentations are permitted. Written and Transplantation Research; 93.856,
and children having, or at risk for, comments should identify the Microbiology and Infectious Diseases
heritable disorders. In addition, individual’s name, address, email, Research, National Institutes of Health, HHS)
ACHDNC’s recommendations regarding telephone number, professional or Dated: October 10, 2017.
inclusion of additional conditions and organization affiliation, background or
Natasha M. Copeland,
inherited disorders for screening which area of expertise (i.e., parent, family
Program Analyst, Office of Federal Advisory
have been adopted by the Secretary are member, researcher, clinician, public
Committee Policy.
then included in the Recommended health, etc.) and the topic/subject
[FR Doc. 2017–22259 Filed 10–13–17; 8:45 am]
Uniform Screening Panel (RUSP). matter.
BILLING CODE 4140–01–P
Conditions listed on the RUSP Individuals who plan to attend and
constitute part of the comprehensive need special assistance, such as sign
preventive health guidelines supported language interpretation or other DEPARTMENT OF HEALTH AND
by HRSA for infants and children under reasonable accommodations, should HUMAN SERVICES
section 2713 of the Public Health notify Ann Ferrero using the address
Service Act, codified at 42 U.S.C. and phone number above at least 10 National Institutes of Health
300gg–13. Under this provision, non- days prior to the meeting.
grandfathered health plans are required National Cancer Institute; Notice of
Amy McNulty,
to cover screenings included in the Closed Meeting
Acting Director, Division of the Executive
HRSA-supported comprehensive
Secretariat. Pursuant to section 10(d) of the
guidelines without charging a co-
payment, co-insurance, or deductible for [FR Doc. 2017–22313 Filed 10–13–17; 8:45 am] Federal Advisory Committee Act, as
plan years (i.e., policy years) beginning BILLING CODE 4165–15–P amended, notice is hereby given of the
on or after the date that is one year from following meeting.
the Secretary’s adoption of the The meeting will be closed to the
DEPARTMENT OF HEALTH AND public in accordance with the
condition for screening.
The meeting agenda will include: (1) HUMAN SERVICES provisions set forth in sections
An update on states’ progress toward 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
National Institutes of Health as amended. The grant applications and
the newborn screening timeliness goals
outlined by the Committee; (2) a National Institute of Allergy and the discussions could disclose
presentation on phase 2 of the spinal Infectious Diseases; Notice of Closed confidential trade secrets or commercial
muscular atrophy evidence review; (3) Meeting property such as patentable material,
presentations on newborn screening and personal information concerning
topics such as the clinical and public Pursuant to section 10(d) of the individuals associated with the grant
health impact of Severe Combined Federal Advisory Committee Act, as applications, the disclosure of which
Immunodeficiency (SCID), carrier status amended, notice is hereby given of the would constitute a clearly unwarranted
in the context of newborn screening, following meeting. invasion of personal privacy.
and a review of long term follow up in The meeting will be closed to the Name of Committee: National Cancer
newborn screening; and (4) updates public in accordance with the Institute Special Emphasis Panel;
from the Laboratory Standards and provisions set forth in sections Translational Studies on Adducts For Cancer
Procedures workgroup, Follow-up and 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Risk Identification and Prevention.
ethrower on DSK3G9T082PROD with NOTICES

Treatment workgroup, and Education as amended. The grant applications and Date: November 8, 2017.
and Training workgroup. The the discussions could disclose Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
Committee will not be voting on a confidential trade secrets or commercial applications.
proposed addition of a condition to the property such as patentable material, Place: National Cancer Institute, Shady
RUSP. Agenda items are subject to and personal information concerning Grove, 9609 Medical Center Drive, Room
change. The final meeting agenda will individuals associated with the grant 7W108, Rockville, MD 20850, (Telephone
be available 2 days prior to the meeting applications, the disclosure of which Conference Call).

VerDate Sep<11>2014 16:59 Oct 13, 2017 Jkt 244001 PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 E:\FR\FM\16OCN1.SGM 16OCN1

Document Created: 2017-10-14 01:42:34
Document Modified: 2017-10-14 01:42:34

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		November 6-9, 2017.
FR Citation		82 FR 48104

82 FR 48104 - National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 82, Issue 198 (October 16, 2017)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health